HAIFA, Israel and MIAMI, Florida – INSIGHTEC®, a commercial-stage medical technology company revolutionizing surgery with incisionless MRI-guided focused ultrasound (MRgFUS) announced today the closing of a $150 million Series E private equity investment round. Koch Disruptive Technologies (KDT), a subsidiary of Koch Industries, focused on finding and funding innovative and emerging companies, led the round with a $100 million investment.
Researchers say the approach breaks new ground in treating cancer non-invasively and with unprecedented precision.
The nicotine in e-cigarettes seems to damage DNA in ways that may increase cancer risk, a new study in mice suggests.
Emaptica's Embrace, the consumer-facing wearable for epileptic seizure detection, received 510(k) clearance from the FDA last month. The wearable, which has already been used in clinical trials by pharma company Sunovion, has a long history that's led it up to this milestone.
It's not uncommon to see customers paying for coffee or boarding a flight using a QR code from their smartphone, but some researchers are now looking to create an edible medication QR code. Researchers at the University of Copenhagen recently published a study in the International Journal of Pharmaceutics which looks at creating QR-encoded smart oral medication made by inkjet printing.
Hospitals and healthcare providers remain under cyber attack, causing organizations to spend more to protect their systems and patient data.
The number of men dying from prostate cancer has overtaken the number of women dying from breast cancer for the first time, with the disease now the UK’s third biggest cancer killer.
Roche’s balovaptan has picked up a Breakthrough Therapy Designation in the US for its potential as a treatment for people with autism spectrum disorder (ASD), potentially placing the drug on a faster path to market.
Administration (FDA) has approved ZOMACTON® (somatropin) for Injection 5 mg and 10 mg recombinant human growth hormone (GH) indicated for replacement of GH in adults with GH deficiency.
GSK China and Ali Health jointly announced a strategic partnership to launch an innovative adult vaccination service system. The system will include online disease education and consultation, online HCP appointment booking, and deliver convenient online-to-offline (O2O) end-to-end service for users. Moreover, community healthcare service centres nationwide can utilise this platform to manage vaccination enquiries and requests. This will help enhance efficiency at the centres and help reduce costs and workload, thus optimising public healthcare institutions’s resources. By year-end, the platform is expected to cover 1500 community healthcare service centres in more than one hundred cities nationwide, including Beijing, Shanghai, Guangzhou, Shenzhen, Hangzhou, Nanjing and Wuhan.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.